S16 Ep13: Positive Phase 3 Data Drive Varegacestat Development in Desmoid Tumors: With Rashmi Chugh MD episode artwork

EPISODE · Feb 26, 2026 · 10 MIN

S16 Ep13: Positive Phase 3 Data Drive Varegacestat Development in Desmoid Tumors: With Rashmi Chugh MD

from OncLive® On Air · host OncLive® On Air

Welcome to OncLive On Air®! I’m your host today, Courtney Flaherty.OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.In today’s episode, Rashmi Chugh, MD, sat down with OncLive to discuss the ongoing development of the investigational γ-secretase inhibitor varegacestat (formerly AL102) for patients with desmoid tumors.Chugh is a clinical professor and service chief of Internal Medicine at the University of Michigan Medical School, as well as an oncologist at the University of Michigan Rogel Cancer Center in Ann Arbor.In the exclusive interview, Dr Chugh expanded on the current unmet needs and treatment goals in desmoid tumors, the biologic rationale for γ-secretase inhibition and emerging biomarker considerations, and the potential clinical role of varegacestat based on positive topline data from the phase 2/3 RINGSIDE trial (NCT04871282).Of note, submission of a new drug application to the FDA for this agent in progressing desmoid tumors is planned for the second quarter of 2026._____That’s all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!Thanks again for listening to OncLive On Air.*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive.

Episode metadata supplied by the publisher feed · Published Feb 26, 2026

Embed this episode

Rashmi Chugh, MD, discusses the ongoing development of the investigational γ-secretase inhibitor varegacestat for patients with desmoid tumors.

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

S16 Ep13: Positive Phase 3 Data Drive Varegacestat Development in Desmoid Tumors: With Rashmi Chugh MD

0:00 10:40

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncLive® On Air?

This episode is 10 minutes long.

When was this OncLive® On Air episode published?

This episode was published on February 26, 2026.

Can I download this OncLive® On Air episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!